whatshot

VKTX   $39.33  -3.13% Market Closed After Close 39.031 -0.76%

Viking Therapeutics Inc
show_chart Advanced Chart of VKTX
Last Events:

2024-02-27 The hottest instrument.

2023-08-05 Trend pattern changed from сужающийся канал to нисходящий клин.

2023-08-05 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: main and signal line crossing.

2023-08-05 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: exit from the oversold zone.

2023-08-04 Trend pattern changed from нисходящий клин to сужающийся канал.

2023-08-03 Signal in RSI changed from bullish reversal to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-02 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-08-02 Trend changed from flat and up to linear up.

Current temperature: 8.59
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 13
Target Price Mean 113.38
Mean unverified/preliminary 113.38 / 113.38
Target Price Low / High 74.00 / 164.00
Median / STD DEV 110.00 / 20.44
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy None
rsi ActivelyBuy ActivelyBuy None
macd None None None
stoch None None None
ma20 Buy ActivelyBuy None
ma50 Sell None None
ma100 Buy ActivelyBuy None
Candlestick PatternJan. 2, 2025 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US92686J1060
ceo Dr. Brian Lian Ph.D.
Website https://www.vikingtherapeutics.com
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.